Nothing Special   »   [go: up one dir, main page]

EP3139914B1 - Compounds for treating ophthalmic diseases and disorders - Google Patents

Compounds for treating ophthalmic diseases and disorders Download PDF

Info

Publication number
EP3139914B1
EP3139914B1 EP15720340.7A EP15720340A EP3139914B1 EP 3139914 B1 EP3139914 B1 EP 3139914B1 EP 15720340 A EP15720340 A EP 15720340A EP 3139914 B1 EP3139914 B1 EP 3139914B1
Authority
EP
European Patent Office
Prior art keywords
compound
eye
ocular
use according
month
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP15720340.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3139914C0 (en
EP3139914A1 (en
Inventor
Stefan Sperl
Franz Obermayr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kiora Pharmaceuticals GmbH
Original Assignee
Kiora Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kiora Pharmaceuticals GmbH filed Critical Kiora Pharmaceuticals GmbH
Publication of EP3139914A1 publication Critical patent/EP3139914A1/en
Application granted granted Critical
Publication of EP3139914C0 publication Critical patent/EP3139914C0/en
Publication of EP3139914B1 publication Critical patent/EP3139914B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans or animals. More particularly, it relates to DHODH inhibitor compounds and their use for the treatment of ophthalmic diseases and disorders.
  • the invention also relates to the administration of such ophthalmic compositions, either for topical treatment or in particular to their intravitreal administration.
  • the invention relates also to the controlled release of therapeutic active agents, in particular of DHODH inhibitor compounds intraocularly, in particular in the posterior segment of the eye.
  • Ocular surface diseases encompass a plethora of pathologies with overlapping conditions leading to common sequels: dysfunction of the ocular tear film and/or the integrity of the ocular surface.
  • the ocular surface is richly innervated by sensory nerves, therefore, any stimulus that affects these tissues can lead to a variety of symptoms. These range from mild discomfort to grittiness, foreign body sensation, irritation, and dryness affecting the quality of life of millions.
  • inflammation can cause damage to the various structures of the ocular surface: i.e. scarring of tissues underlying the conjunctival epithelium and destruction of the Becher-cells leading to dry eyes and/or causing irregularity of the corneal surface that might result in glare.
  • the condition is chronic with surface damage, it might lead to mild to profound decreases in vision as seen in severe dry eyes syndromes, vernal keratoconjunctivitis or infectious diseases as trachoma.
  • Uveitis is an inflammatory and chronic disease of the eye affecting the uvea, the middle, pigmented layer of the eye. Apart from corticosteroids and immunosuppressives no treatment is currently available. Both classes of drugs are known to cause serious side effects when used for a prolonged time period, needed to treat chronic uveitis. Such side effects include osteoporosis, extreme weight gain, diabetes etc. Autoimmune uveitis is associated with immunological response by T helper cells (Th1 and Th17) to human retinal or cross-reactive proteins. These autoreactive T helper cells migrate and infiltrate the eye and are the main cause of the inflammation of the eye. It has been shown in animal models and in humans that neutralizing these deregulated T cells (hallmark cytokines: IFN- ⁇ for Th1 and IL-17 for Th17) lead to an amelioration of clinical uveitis.
  • T helper cells Th1 and Th17
  • Uveitis is one of the leading causes of blindness in the world and the fourth leading cause in the western world and several million patients suffer from any form of uveitis which can occur in any age group.
  • Conjunctivitis (often called "pink eye") is an inflammation of the conjunctiva, which is the mucous membrane covering the white part of the eye and the inner side of the eyelid.
  • conjunctivitis The most common form of conjunctivitis is caused by adenoviral infection. This type of conjunctivitis may also spread to affect the cornea (keratitis), and may persist for several weeks and cause hazy vision. Since the disease is often epidemic in nature, it is called epidemic keratoconjunctivitis (EKC). EKC is a serious and contagious form of conjunctivitis (conjunctiva and cornea).
  • EKC e.g., a chronic obstructive pulmonary disease
  • Symptoms of EKC include acute onset of watering redness, foreign body sensation and severe pain, diminished eyesight, tearing, and sensitivity to light.
  • an immune T cell mediated infiltration of the corneal stroma that results in deteriorating vision is observed.
  • Millions of patients suffer from viral conjunctivitis which can occur in any age group. Currently no antiviral treatment is available.
  • Therapeutic agents for treating ocular conditions are known, but typically those agents are associated with the development of one or more side-effects.
  • ocular corticosteroid treatment Prednisolon or Dexamethason
  • PGF2 prostaglandin treatments
  • WO2007038687 disclose a method for minimizing systemic exposure to a steroid-sparing immunosuppressive agent by administering said agent directly into an eye of a subject having or at risk for having an ocular disease.
  • EP0413329 describe the use of leflunomide for the treatment of ocular diseases with immune etiology.
  • DHODH inhibitors like leflunomide and teriflunomide are used systemically to treat diseases like rheumatoide arthritis and multiple sclerosis.
  • Fang et al. described the systemic use of leflunomide to treat experimental autoimmune uveitis in rats ( Fang CB, et al. (2013) Amelioration of Experimental Autoimmune Uveitis by Leflunomide in Lewis Rats. PLoS ONE 8(4): e62071 ).
  • high systemic drug exposure is needed to treat the eye disease uveitis.
  • leflunomide is known to have the potential to cause severe liver toxicity, this approach would have a low risk-benefit ratio.
  • it is generally favorable to avoid systemic drug exposure and potential systemic side effects in order to treat local eye diseases.
  • EPQ4133292 discloses the use of leflunomide for the treatment of ocular diseases.
  • Sung et al. describes an intravitreal controlled release implant of leflunomide for the treatment of uveitis ( Sung et al., Proceedings of the international Symposium on Controlled Release of Bioactive Materials, 26th, 38-39, 1999 ).
  • US2011275603 describes dihydroorotate dehydrogenase inhibitors for the treatment of ocular diseases such as uveitis and allergic conjunctivitis.
  • WO2006022442 discloses heterocyclic amide compounds as DHODH inhibitors.
  • WO2004056797 discloses DHODH inhibitors (e.g, 3-(2,3,5,6-tetrafluoro-3'-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid) and their use in the treatment of uveitis.
  • DHODH inhibitors e.g, 3-(2,3,5,6-tetrafluoro-3'-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid
  • WO2004056747 discloses DHODH inhibitors, which are capable of binding to the ubiguinone binding site of DHODH, and their use in the treatment of uveitis.
  • WO2008077639 describes amino nicotinic and isonicotinic compounds as DHODH inhibitors and their use in the treatment of conjunctivitis and uveitis.
  • PP-001 (3-(2,3,5,6-tetrafluoro-3'-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid), a DHODH inhibitor compound is highly efficacious and well tolerated to treat eye diseases by local administration to the eye.
  • the present invention provides a method to treat an ocular disease or condition, wherein an effective amount of PP-001 is locally administered to the eye of a subject in need thereof.
  • the method relates to PP-001 for use in local drug delivery in a method to treat an ocular disease.
  • the ocular disease or condition to be treated can be uveitis, optic neuritis, retrobulbar neuritis, ocular inflammation or discomfort or trauma caused by or associated with the use of contact lenses, ocular inflammation, dry eye, discomfort or trauma caused by or associated with refractive surgery, macular degeneration, optionally radial keratotomy or astigmatic keratotomy, blepharitis, an optic nerve disease or disorder, optionally papilledema or a conjunctivitis condition, optionally allergic conjunctivitis, pink eye, giant papillary conjunctivitis, infectious conjunctivitis or chemical conjunctivitis.
  • PP-001 (3-(2,3,5,6-tetrafluoro-3'-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid), a DHODH inhibitor compounds is effective in treating ocular diseases, conditions or symptoms related thereto by ameliorating inflammation and/or by increasing healing or repair of injured ocular tissue or cells.
  • Enhanced cell or tissue repair would slow ocular disease progression, enhance recovery or render an existing disease (usually mild to moderate) sub-clinical or nearly sub-clinical.
  • DHODH inhibitor compounds for use in local drug delivery in the treatment of an ocular disease.
  • DHODH inhibitor compounds which are not forming part of the claimed invention, but are useful for understanding the invention, selected from the group consisting of leflunomide, teriflunomide, vidofludimus, brequinar, ASLAN003 or a compound of general formula I, wherein
  • DHODH inhibitor compounds which are not forming part of the claimed invention, but are useful for understanding the invention, of general formula I, wherein A is furan, thiophene, pyridyl, phenyl; dihydrothiophene, cyclopentenyl or cyclopentadienyl and the other residues are as defined above.
  • inhibitor compounds of general formula I which are not forming part of the claimed invention, but are useful for understanding the invention, wherein A is thiophene and the other residues are as defined above.
  • DHODH inhibitor compounds of general formula I which are not forming part of the claimed invention, but are useful for understanding the invention, wherein Z 1 and Z 2 are O.
  • DHODH inhibitor compounds of general formula I which are not forming part of the claimed invention, but are useful for understanding the invention, wherein E is phenyl optionally substituted by R' and the other residues are as defined above.
  • DHODH inhibitor compounds of general formula I which are not forming part of the claimed invention, but are useful for understanding the invention, wherein Y is phenyl optionally substituted by R' and the other residues are as defined above.
  • DHODH inhibitor compounds depicted in the following list*, which are not forming part of the claimed invention, but are useful for understanding the invention.
  • the embodiment according to the invention is the DHODH inhibitor comoound for use as described above, wherein the comoound is PP-001 (3-(2,3,5,6-tetrafluoro-3'-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid) possesses pronounced antiviral activity.
  • Leflunomide (5-methyl- N -[4-(trifluoromethyl) phenyl]-isoxazole-4-carboxamide) is an immunosuppressive disease-modifying anti-rheumatic drug (DMARD) used in active moderate to severe rheumatoid arthritis and psoriatic arthritis.
  • DMARD immunosuppressive disease-modifying anti-rheumatic drug
  • Teriflunomide ((2Z)-2-cyano-3-hydroxy- N -[4-(trifluoromethyl)phenyl]but-2-enamide) is the active metabolite of leflunomide, a disease-modifying agent used in the treatment of multiple sclerosis (MS).
  • Brequinar (6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid sodium salt) was originally developed as an anti-proliferative agent for the treatment of cancer.
  • Vidofludimus (2-(3-fluoro-3'-methoxybiphenyl-4-ylcarbamoyl)-cyclopent-1-enecarboxylic acid has been shown to be active in rodent models of arthritis, multiple sclerosis, psoriasis, and systemic lupus erythematosus. It has been shown to be active in clinical phase two studies to treat rheumatoid arthritis (RA) and inflammatory bowel disease (IBD).
  • RA rheumatoid arthritis
  • IBD inflammatory bowel disease
  • DHODH inhibitors are described, for example, in WO2004056747 , WO2004056797 , WO2009021696 and WO2011138665 .
  • alkyl when used alone or in combination with other groups or atoms, refers to a saturated straight or branched chain consisting solely of 1 to 6 hydrogen-substituted carbon atoms, and includes methyl, ethyl, propyl, isopropyl, n-butyl, 1-methylpropyl, isobutyl, t-butyl, 2,2-dimethylbutyl, n-pentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, n-hexyl and the like.
  • alkenyl refers to a partially unsaturated straight or branched chain consisting solely of 2 to 6 hydrogen-substituted carbon atoms that contains at least one double bond, and includes vinyl, allyl, 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1,3-dienyl, penta-1,3-dienyl, penta-2,4-dienyl, 2-methylbut-1-enyl, 2-methylpent-1-enyl, 4-methylpent-1-enyl, 4-methylpent-2-enyl, 2-methylpent-2-enyl, 4-methylpenta-1,3-dienyl, hexen-1-yl and the like.
  • alkynyl refers to a partially unsaturated straight or branched chain consisting solely of 2 to 8 hydrogen-substituted carbon atoms that contains at least one triple bond, and includes ethynyl, 1-propynyl, 2-propynyl, 2-methylprop-1-ynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1,3-butadiynyl, 3-methylbut-1-ynyl, 4-methylbut-ynyl, 4-methylbut-2-ynyl, 2-methylbut-1-ynyl, 1-pentynyl,2-pentynyl, 3-pentynyl, 4-pentynyl, 1 ,3-pentadiynyl, 1,4-pentadiynyl, 3-methylpent-1-ynyl, 4-methylpent-2-ynyl, 4-methylpent-2-ynyl, 4-methylpent-2-yn
  • cycloalkyl when used alone or in combination with other groups or atoms, refers to a saturated or unsaturated ring consisting solely of 3 to 8 carbon atoms, that may optionally be substituted with one or more, identical or different substituents, suitably one to three substituents, independently selected from C 1-4 alkyl, fluoro-substituted C 1-4 alkyl, halo, OC 1-4 alkyl, fluoro-substituted OC 1-4 alkyl, NH 2 , NH(alkyl), N(alkyl) 2 , CO 2 H, CO 2 (alkyl), NO 2 and CN.
  • cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl and the like.
  • Non-limiting examples of the heterocycloalkyl group are azepan-1-yl, piperidinyl, in particular piperidin-1-yl and piperidin-4-yl, piperazinyl, in particular N-piperazinyl and 1-alkylpiperazine-4-yl, morpholine-4-yl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrothiophen, sulfolanyl, sulfolenyl, oxazolinyl, isoxazolinyl, oxazolidinyl, oxazolidinon-yl, wherein in the aforementioned groups optionally one or more of the hydrogen atoms is replaced by a residue R a as defined above.
  • aryl refers to an aromatic mono- or bicyclic group containing from 6 to 14 carbon atoms that may be optionally fused with a fully or partially saturated or unsaturated carbocyclic ring and may optionally be substituted with one or more, identical or different substituents, suitably one to three substituents, independently selected from C 1-4 alkyl, fluoro-substituted C 1-4 alkyl, halo, - OC 1-4 alkyl, fluoro-substituted OC 1-4 alkyl, NH 2 , NH(alkyl), N(alkyl) 2 , CO 2 H, CO 2 (alkyl), NO 2 and CN.
  • aryl groups include phenyl, naphthyl, indanyl, and the like.
  • heteroaryl refers to an aromatic mono- or bicyclic group containing from 5 to 14 carbon atoms, of which one to five is replaced with a heteroatom selected from N, S and O, that may optionally be reduced to a nonaromatic heterocycle and may optionally be substituted with one or more, identical or different substituents, suitably one to three substituents, independently selected from C 1-4 alkyl, fluoro-substituted C 1-4 alkyl, halo, OC 1-4 alkyl, fluoro-substituted OC 1-4 alkyl, NH 2 , NH(alkyl), N(alkyl) 2 , CO 2 H, CO 2 (alkyl), NO 2 and CN.
  • heteroaryl groups include pyrrolyl, dihydropyrrolyl, pyrrolidinyl, indolyl, isoindolyl, indolizinyl, imidazolyl, pyrazolyl, benzimidazolyl, imidazo(1,2-a)pyridinyl, indazolyl, purinyl, pyrrolo(2,3-c)pyridinyl, pyrrolo(3,2-c)pyridinyl, pyrrolo(2,3-b)pyridinyl, pyrazolo(1,5-a)pyridinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, oxazolyl, isoxazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-oxadiazolyl, thiazolyl, isothiazolyl,
  • a halogen residue is chlorine, bromine, fluorine or iodine, fluorine being preferred.
  • Ocular diseases are for example, uveitis, optic neuritis, retrobulbar neuritis, ocular inflammation or discomfort or trauma caused by or associated with the use of contact lenses, ocular inflammation, dry eye syndrome, discomfort or trauma caused by or associated with refractive surgery, such as for example radial keratotomy or astigmatic keratotomy, macular degeneration, blepharitis, an optic nerve disease or disorder, such as for example papilledema or a conjunctivitis condition, such as for example allergic conjunctivitis, pink eye, giant papillary conjunctivitis, infectious conjunctivitis or chemical conjunctivitis.
  • Uveitis is an inflammatory and chronic disease of the eye affecting the uvea, the middle, pigmented layer of the eye.
  • the uvea comprises three parts: the iris (responsible for color), the ciliary body (positioned behind the iris and responsible for lubrication of the eye) and the choroid (vascular lining tissue below the retina).
  • the iris responsible for lubrication of the eye
  • the choroid vascular lining tissue below the retina.
  • Both classes of drugs are known to cause serious side effects when used for a prolonged time period, needed to treat chronic uveitis. Such side effects include osteoporosis, extreme weight gain, diabetes etc.
  • T helper cells (Th1 and Th17) to human retinal or cross-reactive proteins. These autoreactive T helper cells migrate and infiltrate the eye and are the main cause of the inflammation of the eye. It has been shown in animal models and in humans that neutralizing these deregulated T cells (hallmark cytokines: IFN- ⁇ for Th1 and IL-17 for Th17) lead to an amelioration of clinical uveitis.
  • DHODH inhibitors are already used to treat inflammatory diseases, e.g. Arava ® to treat rheumatoid arthritis or Aubagio ® to treat multiple sclerosis.
  • such medications are provided as tablets or intravenous injections and gain therapeutic activity by having a systemic effect on the whole body.
  • Fang CB et al. (2013) have also been shown previously that systemic administration of the DHODH inhibitor Leflunomide is useful to treat experimental autoimmune uveitis in a rat model.
  • Leflunomide due to the ocular-blood-barrier, very high systemic blood levels of Leflunomide are necessary to reach therapeutically efficient drug levels in the eye. Such high blood levels of an immunosuppressive drug may result in inadequate systemic side effects when treating an eye disease.
  • the DHODH inhibitor compound PP-001 is highly efficacious and well tolerated when used to treat eye diseases by local administration to the eye.
  • a further embodiment of the invention relates to the DHODH inhibitor compound PP-001 for use in the treatment of uveitis.
  • conjunctivitis The most common form of conjunctivitis is caused by adenoviral infection. This type of conjunctivitis may also spread to affect the cornea (keratitis), and may persist for several weeks and cause hazy vision. Since the disease is often epidemic in nature, it is called epidemic keratoconjunctivitis - EKC is a serious and contagious form of conjunctivitis (conjunctiva and cornea). A recent outbreak of adenoviral conjunctivitis in northern Germany in December 2012 was a major topic in the daily news. The majority of cases of EKC are believed to be caused by a select species of adenoviruses, including Ad8, Ad19 and Ad37.
  • a further embodiment of the invention relates to the DHODH inhibitor compound PP-001for use in the treatment of conjunctivitis.
  • Adenoviruses are known to cause upper and lower respiratory tract infections, several varieties of viral conjunctivitis (including keratoconjunctivitis), as well as gastroenteritis and hemorrhagic cysts, though only certain serotypes are associated with each. With regard to ocular infections, adenoviruses present a serious public health risk and are responsible for 65 to 90% of viral conjunctivitis and 15 to 70% of all cases of infectious conjunctivitis worldwide.
  • a further embodiment of the invention relates to the DHODH inhibitor compound PP-001for use in the treatment of an ocular disease caused by an adenovirus.
  • Keratoconjunctivitis sicca also called keratitis sicca, xerophthalmia or dry eye syndrome (DES) is an eye disease caused by eye dryness, which, in turn, is caused by either decreased tear production or increased tear film evaporation. It is found in humans and some animals. KCS is the most common eye disease, affecting 5-6% of the population.
  • a further embodiment of the invention relates to the DHODH inhibitor compound PP-001for use in the treatment of dry eye syndrome.
  • Age-related macular degeneration is a medical condition that usually affects older adults and results in a loss of vision in the center of the visual field (the macula) because of damage to the retina. It occurs in “dry” and “wet” forms. It is a major cause of blindness and visual impairment in older adults (>50 years).
  • wet AMD wet AMD
  • wet AMD wet AMD
  • Wet AMD has a prevalence of around 1.5% among the population.
  • a further embodiment of the invention relates to the DHODH inhibitor compound PP-001for use in the treatment of wet age-related macular degeneration.
  • DHODH inhibitor compounds which are not forming part of the claimed invention, but are useful for understanding the invention, which are administered to a subject in a therapeutically effective amount.
  • the term "subject" can be any singular or plural subject, including, but not limited to humans and animals, e.g. mammals or birds, specifically from horses, poultry, pigs, cattle, rodents and pets. Said subjects can be healthy subjects or any subjects suffering or going to suffer from an ocular disease.
  • the terms “therapeutically effective amount” or “effective amount” refer to the amount of drug required to confer a biological or meaningful subject benefit, such as the biological or medical response or improvement sought by a medical doctor or other medical professional.
  • the terms “therapeutically effective amount” or “effective amount” are intended to mean the amount of drug that will bring about a biologically meaningful improvement in the subject's ocular disorder, symptom, or disease. Doses that exhibit large therapeutic indices are preferred. Effective amounts may vary, as recognized by those skilled in the art, depending, for example, on route of administration, dosage form, inclusion of additional active agents, as well as age, weight, sensitivity, and health of the subject.
  • the treatment regimen for the ocular disease can vary depending on the particular needs of the subject.
  • the dose and frequency of administration of the DHODH inhibitor compound may depend in part on the age of the subject and severity of ocular disease and the route of administration.
  • the DHODH inhibitor may be applied topically (e.g. in form of eye drops) between once daily and up to eight times a day.
  • Some patients may benefit from regular application of the formulation, such as for at least for about 3 days, in another aspect at least for about 10 days, in a further aspect for at least about 1 month and yet in another aspect at least for about 3 months.
  • a shorter or longer treatment regimen may be used, if desired.
  • the DHODH inhibitor may also be applied into the eye, e.g. as intravitreal injection or implant. In contrast to topical eye drops, injections are applied significantly less frequent.
  • Intravenous injection, oral administration or a intravitreous injection are attempted to administer the drugs for the diseases of the posterior segments of the eye.
  • the intravenous injection and the oral administration can deliver only a very small amount of drugs to the posterior segments of the eye which are target sites, and sometimes causes unexpected strong systemic actions (side effects) of the drugs.
  • the amount of the drug to be delivered to the posterior segments of the eye is larger than those of the intravenous injection and the oral administration.
  • a formulation for intravitreal injections releases the drug continuously over a longer period of time at a release rate which ensures continuous therapeutic concentration at the desired site of action of the DHODH inhibitor.
  • examples for such formulations are PLGA nano-spheres or PLGA microspheres.
  • the DHODH inhibitor is embedded in small spheres of PLGA polymers and slowly released within the eye while the PLGA is degraded.
  • complete drug can be released within 1 week to 1 month, preferred within 6 months, and more preferred within 12 months or longer periods.
  • a slow release of therapeutically active amounts of the DHODH inhibitor from the formulation after intravitreal injection aims to reduce the intervals between single injections into the eye. Similar results can be obtained with implants.
  • the active ingredient of the invention may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form a pharmaceutical composition.
  • the active ingredient of the invention may be administered locally to the eyes of the subjects to be treated for avoiding the potential negative side effects of the administration in the systemic circulation.
  • the pharmaceutical composition of the invention is formulated for a local ocular route administration such as intravitreous, topical, periocular injections (subconjunctival, peribulbar, laterobulbar, retrobulbar, subtenon, suprachoroidal), intra- or periocular implants (intrascleral, periscleral, episcleral), intravitreous implants or suprachoroidal implants or particles or polymeric composition, or any releasing systems such as emulsions, solid non-biodegradable or degradable implants or tablets, mini pumps or any topical formulations.
  • a local ocular route administration such as intravitreous, topical, periocular injections (subconjunctival, peribulbar, laterobulbar, retrobulbar, subtenon, suprachoroidal), intra- or periocular implants (intrascleral, periscleral, episcleral), intravitreous implants or suprachoroidal implants or particles or polymeric composition, or any releasing systems such as emulsions,
  • the pharmaceutical composition contains vehicles which are pharmaceutically acceptable for a formulation capable of being injected into the eye.
  • vehicles which are pharmaceutically acceptable for a formulation capable of being injected into the eye.
  • These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions.
  • compositions suitable for injectable use in the eye include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and may be preserved against the contaminating action of microorganisms, such as bacteria, virus and fungi.
  • Solutions comprising the DHODH inhibitor compound PP-001 of the invention as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
  • the carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetables oils.
  • the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, benzalkonium chloride, and the like.
  • isotonic agents for example, sugars or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.
  • Sterile injectable solutions for the eyes are prepared by incorporating the active ingredients of the invention in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • solutions Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as it is therapeutically effective.
  • the formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like may also be employed.
  • the active ingredient may be also delivered directly to the eye by ocular tissue injection such as periocular, conjunctival, subtenon, intracameral, intravitreal, intraocular, subretinal, subconjunctival, retrobulbar, suprachoroidal or intracanalicular injections; by direct application to the eye using a catheter or other placement device such as a retinal pellet, intraocular insert, suppository or an implant comprising a porous, non-porous, or gelatinous material; by topical ocular drops or ointments; or by a slow release device in the cul-de-sac or implanted adjacent to the sclera (transscleral) or in the sclera (intrascleral) or suprachoroidal or within the eye.
  • Intracameral injection may be through the cornea into the anterior chamber to allow the agent to reach the trabecular meshwork.
  • Intracanalicular injection may be into the venous collector channels draining Schlemm's
  • the active ingredient may be combined with ophthalmologically acceptable preservatives, co-solvents, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride, or water to form an aqueous, sterile ophthalmic suspension or solution.
  • Solution formulations may be prepared by dissolving the active ingredient in a physiologically acceptable isotonic aqueous buffer. Further, the solution may include an acceptable surfactant to assist in dissolving the active ingredient.
  • Viscosity building agents such as hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, methylcellulose, carboxymethylcellulose, polyvinylpyrrolidone, hyaluronic acid, or the like may be added to the compositions of the present invention to improve the retention of the compound.
  • a sterile ophthalmic ointment formulation the active ingredient is combined with a preservative in an appropriate vehicle, such as mineral oil, liquid lanolin, or white petrolatum.
  • an appropriate vehicle such as mineral oil, liquid lanolin, or white petrolatum.
  • Sterile ophthalmic gel formulations may be prepared by suspending the active ingredient in a hydrophilic base prepared from the combination of, for example, CARBOPOL ® -940 (BF Goodrich, Charlotte, NC), or the like, according to methods known in the art.
  • VISCOAT ® Alcon Laboratories, Inc., Fort Worth, TX
  • intraocular injection for example.
  • compositions of the present invention may contain penetration enhancing agents such as cremophor and TWEEN ® 80 (polyoxyethylene sorbitan monolaureate, Sigma Aldrich, St. Louis, MO), in the event the active ingredient is less penetrating in the eye.
  • penetration enhancing agents such as cremophor and TWEEN ® 80 (polyoxyethylene sorbitan monolaureate, Sigma Aldrich, St. Louis, MO), in the event the active ingredient is less penetrating in the eye.
  • the pharmaceutical composition of the invention is an ophthalmic drop formulation.
  • the eye drop is provided in any formulation generally used, for example, in the form of an aqueous eye drop such as aqueous eye drop solution, aqueous eye drop suspension, viscous eye drop solution, solubilized eye drop solution and the like, or in the form of a non-aqueous eye drop such as a non-aqueous eye drop solution, non-aqueous eye drop suspension and the like.
  • the composition of the present invention is prepared as an aqueous eye drop, it preferably contains an additive which is usually used in an aqueous eye drop.
  • the examples of such an additive include preservatives, isotonic agents, buffering agents, stabilizer, pH regulators or the like.
  • the active ingredient of the invention is delivered through a biodegradable ocular implant.
  • the implants can be formed in a manner that the active ingredient is homogenously distributed or dispersed throughout the biodegradable polymer matrix. Additionally, the implants can be formed to release the active ingredient into an ocular region of the eye over various time periods. Thus, the active ingredient can be released from implants made according to the present invention for a period of time, for example, 30-200 days.
  • the active ingredient can comprise from about 10% to about 90% by weight of the implant.
  • the agent is from about 40% to about 80% by weight of the implant.
  • the agent comprises about 60% by weight of the implant
  • the active ingredient can be homogeneously dispersed in the biodegradable polymer of the implant.
  • the implant can be made, for example, by a sequential or double extrusion method.
  • the selection of the biodegradable polymer used can vary with the desired release kinetics, subject tolerance, the nature of the disease to be treated, and the like. Polymer characteristics that are considered include, but are not limited to, the biocompatibility and biodegradability at the site of implantation, compatibility with the active ingredient of interest, and processing temperatures.
  • the biodegradable polymer matrix usually comprises at least about 10, at least about 20, at least about 30, at least about 40, at least about 50, at least about 60, at least about 70, at least about 80, or at least about 90 weight percent of the implant. In one variation, the biodegradable polymer matrix comprises about 40% to 50% by weight of the implant.
  • Biodegradable polymers which can be used include, but are not limited to, polymers made of monomers such as organic esters or ethers, which when degraded result in physiologically acceptable degradation products. Anhydrides, amides, orthoesters, or the like, by themselves or in combination with other monomers, may also be used.
  • the polymers are generally condensation polymers.
  • the polymers can be crosslinked or non-crosslinked. If crosslinked, they are usually not more than lightly crosslinked, and are less than 5% crosslinked, usually less than 1% crosslinked. Of particular interest are polymers of hydroxyaliphatic carboxylic acids, either homo- or copolymers, and polysaccharides.
  • polyesters of interest include homo- or copolymers of D-lactic acid, L-lactic acid, racemic lactic acid, glycolic acid, caprolactone, and combinations thereof.
  • Copolymers of glycolic and lactic acid are of particular interest, where the rate of biodegradation is controlled by the ratio of glycolic to lactic acid.
  • the percent of each monomer in poly(lactic-co-glycolic)acid (PLGA) copolymer may be 0-100%, about 15-85%, about 25-75%, or about 35-65%. In certain variations, 25/75 PLGA and/or 50/50 PLGA copolymers are used. In other variations, PLGA copolymers are used in conjunction with polylactide polymers or polyurethanes.
  • buffering agents and preservatives may be employed.
  • Preservatives which may be used include, but are not limited to, sodium bisulfite, sodium bisulfate, sodium thiosulfate, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate, phenylmercuric nitrate, methylparaben, polyvinyl alcohol and phenylethyl alcohol.
  • buffering agents that may be employed include, but are not limited to, sodium carbonate, sodium borate, sodium phosphate, sodium acetate, sodium bicarbonate, and the like, as approved by the FDA for the desired route of administration.
  • Electrolytes such as sodium chloride and potassium chloride may also be included in the formulation.
  • the formulation according to the invention may further comprise an antiphlogistic or antibiotic agent like azithromycin, specifically an agent with additional antiinflammatory properties, specifically histamine antagonists or non-steroidal antiinflammatory drugs.
  • an antiphlogistic or antibiotic agent like azithromycin, specifically an agent with additional antiinflammatory properties, specifically histamine antagonists or non-steroidal antiinflammatory drugs.
  • the formulation of the invention may also be formulated as depot formulation which provides continuous or prolonged administration.
  • the formulation can be used in preventing recurrence of ocular infections in a subject.
  • the formulation can be used in preventing recurrence of ocular inflammations in a subject.
  • the formulations of the present invention are stable in a wide range of temperatures.
  • the invention also provides that the formulation be packaged in a hermetically sealed container such as an ampoule or sachette indicating the quantity of formulation.
  • the formulation is supplied as a liquid, in another embodiment, as a dry sterilized lyophilized powder or water free concentrate, or as dry and sterile nano- or microspheres of drug-containing PLGA copolymers in a hermetically sealed container and can be reconstituted, e.g., with water or saline to the appropriate concentration for administration to a subject.
  • the composition is supplied in liquid form in a hermetically sealed container indicating the quantity and concentration of the composition.
  • the invention furthermore comprises the following items:
  • PP-001 was dissolved in PBS and applied intravitreally in 3 different concentrations.
  • Example 2 Prevention of relapses in the experimental autoimmune uveitis rat model by intravitreal injection of PP-001
  • EAU Experimental autoimmune uveitis in Lewis rats is a model for human endogenous uveitis.
  • the disease is mediated by CD4+ T lymphocytes of the T helper 1 (Th1) and Th17 subtypes.
  • Th1 T helper 1
  • IRBP retinal antigens
  • IRBP interphotoreceptor retiniod-binding protein
  • IRBP is also considered to be an autoantigen in humans.
  • Peptide R14 a 23mer from IRBP, is the most pathogenic epitope for Lewis rats. Immunization with these peptides emulsified in Complete Freund's Adjuvant (CFA) leads to severe inflammation of the anterior chamber of the eyes and destruction of the retinal architecture.
  • CFA Complete Freund's Adjuvant
  • R14 causes a relapsing-remitting disease with an early onset (about day 7), the peak of EAU between day 10 to 14 and the remission around day 17/18.
  • PP-001 reduced the number of relapses by >50% Furthermore not only the number of relapses was inhibited after administration of a DHODH inhibitor but also the time to the appearance of the first relapse was delayed in the treatment group compared to the placebo group.
  • Fig. 1 shows the percentage of relapses after single intravitreal treatment with placebo or PP-001.
  • Example 3 Inhibition of choroidal neovascularization
  • Choroidal neovascularization is a known feature of posterior uveitis and a major cause of retinal destruction and loss of vision.
  • the EAU model in Lewis rats was used.
  • Induction with PDSAg causes a monophasic disease with first clinical signs of inflammation observed between day 8 and 12 after immunization and reaching the peak of disease between day 14 and 18. Inflammation in the anterior chamber subsides until day 21 to 22 post immunization. Long term effects such as choroidal neovascularization are seen at the later stages of the disease after the inflammation of the anterior chamber has subsided. 18 Lewis rats were immunized with PDSAg. Starting at the beginning of the disease (day 9 post immunization) 6 animals were treated with PP-001 and 6 animals were treated with vehicle control. Starting at day 15 (peak of the disease) 6 additional animals were treated with PP-001. Post day 25 experiment was stopped and 12 eyes for each treatment group were histological analyzed for the presence of choroidal neovascularizations.
  • PP-001 reduced the number of choroidal neovascularizations by a factor of 3 (p ⁇ 0.005) when treatment was started at the beginning of uveitis (day 9).
  • PP-001 reduced the mean number of choroidal neovascularizations from 6 to 3 (p ⁇ 0.05).
  • Rats were immunized with 25 ⁇ g of the respective peptide as previously described.
  • LN inguinal and para-aortal lymph nodes
  • single cell suspensions were stimulated with the respective antigen peptides at a final concentration of 10 ⁇ g/ml RPMI1640, supplemented with Penicillin/ Streptomycin, L-Glutamine, essential and non-essential amino acids (all 4 from PAA, Colebee, Germany), 12.5 ⁇ M MeOH and 1% normal rat serum.
  • the cells were expanded in culture medium supplemented with 10% spleen conditioned medium (from Concanavalin A-stimulated rat spleen cells) and 5% fetal calf serum (FCS) for 4 days.
  • 10% spleen conditioned medium from Concanavalin A-stimulated rat spleen cells
  • FCS fetal calf serum
  • T cells/ml were incubated with irradiated (8 Gy) rat thymocytes (3-10 fold more than T cells) as antigen-presenting cells (APC) and 10 ⁇ g/ml of the specific antigen peptide in culture medium as described for the first stimulation. After two days of culturing cells were expanded with conditioned medium for 5 days as described above, followed by another cycle of restimulation and expansion.
  • irradiated (8 Gy) rat thymocytes (3-10 fold more than T cells) as antigen-presenting cells (APC)
  • APC antigen-presenting cells
  • test substance was added to the cultures during the first, second and third stimulation with antigen (primary stimulation: 2 ⁇ 10 6 LN cells, no addition of antigen presenting cells (APC) necessary; 2 nd /3 rd restimulation: 0.5 ⁇ 10 6 T cells and 2.5 ⁇ 10 6 irradiated thymocytes per ml; 20 ⁇ g of the respective antigen peptide/ml).
  • primary stimulation 2 ⁇ 10 6 LN cells, no addition of antigen presenting cells (APC) necessary
  • API antigen presenting cells
  • nd /3 rd restimulation 0.5 ⁇ 10 6 T cells and 2.5 ⁇ 10 6 irradiated thymocytes per ml; 20 ⁇ g of the respective antigen peptide/ml.
  • PP-001 dissolved in DMSO was added to final concentrations of 3 ⁇ M, 10 ⁇ M and 30 ⁇ M to triplicate microwell cultures of 100 ⁇ l (final volume). After 24 h supernatants were collected
  • Example 5 In vivo efficacy of PP-001 eye drops in an experimental adenoviral ocular infection in New Zealand White rabbits
  • the rabbits were divided into 5 treatment groups outlined in the chart below.
  • the five treatment groups consisted of a vehicle control, 0.16% PP-001 8 times, 6 times, and 4 times daily for 10 days, and the positive antiviral control 0.5% cidofovir (CDV).
  • Table 1 Group Drug Treatment Regimen n Rabbits n Eyes Rabbit Numbers PP-001-3 0.16% PP-001 8 times daily for 10 days 5 10 1-5 PP-001-2 0.16% PP-001 6 times daily for 10 days 5 10 6-10 PP-001-1 0.16% PP-001 4 times daily for 10 days 5 10 11-15
  • Ad5 titers were determined on A549 cell monolayers using standard plaque assays. The ocular cultures to be titered were thawed, diluted (1:10) and inoculated onto A549 monolayers. The virus was adsorbed for 3 h. Following adsorption, 1 ml of media plus 0.5% methylcellulose was added to each well, and the plates were incubated at 37°C in a 5% CO 2 -water vapor atmosphere.
  • Vehicle control eye drops A solution containing 20 mg/ml polyvinyl-pyrrolidone, 10 mg/ml glycerol 85%, 2 mg/ml hydroxypropyl methylcellulose in sodium phosphate buffer adjusted to pH 7.
  • PP-001 eye drops A solution containing 1.6 mg/ml PP-001, 20 mg/ml polyvinylpyrrolidone, 10 mg/ml glycerol 85%, 2 mg/ml hydroxypropyl methylcellulose in sodium phosphate buffer adjusted to pH 7.
  • Positive control cidofovir eye drops 450 ⁇ l (33.75 mg) of the 75 mg/ml Cidofovir Injection (Mylan Institutional LLC, Rockford, IL Lot #130628, Exp. 05/2015) was added to 6.3 ml of 0.9% sodium chloride for injection USP (Baxter Healthcare Corp. Deerfield, IL) to yield the 6.75 ml of 0.5% cidofovir.
  • the antiviral efficacy of 0.16% PP-001 instilled 8 times and 6 times per day for 10 days was similar to the positive antiviral control, 0.5% cidofovir, instilled twice daily for 7 days (see Fig. 5 ).
  • Example 6 Evaluation of topical administrations of PP-001 in a controlled-environment chamber murine model of dry eye
  • the aim of the study was to evaluate the tolerability and therapeutic potential of PP-001 in a murine model of dry eye syndrome.
  • Dry eye symptoms were induced in forty (40) pigmented C57BL/6N mice by exposing them to a controlled environment (relative humidity ⁇ 25%, air-flow 15L/min, temperature 20-22°C) and systemic scopolamine administration (0.5 mg/72h) for 10 days.
  • mice were randomized into 4 groups of 10 animals and treated with PP-001, Restasis ® , placebo and the forth group remained untreated.
  • Placebo eye drops A solution containing 20 mg/ml polyvinylpyrrolidone, 10 mg/ml glycerol 85%, 2 mg/ml hydroxypropyl methylcellulose in sodium phosphate buffer adjusted to pH 7.
  • PP-001 eye drops A solution containing 1.6 mg/ml PP-001, 20 mg/ml polyvinylpyrrolidone, 10 mg/ml glycerol 85%, 2 mg/ml hydroxypropyl methylcellulose in sodium phosphate buffer adjusted to pH 7.
  • corneal staining scores and tear productions were significantly altered on days 3, 7 and 10, in comparison to baseline values i.e. increasing of the corneal staining and reduction of tear production, except for Placebo group on day 7 on tear production.
  • PP-001 and Restasis ® 0.05% reduced corneal staining on Day 10 when compared to placebo treatment.
  • Example 7 Pharmacokinetic and tolerability of intravitreal injections of PP-001 solutions in Dutch Belted rabbits
  • Dose Volume Dose Vehicle Termination Time Points 1 IVT PP-001 0.0625 mg/eye 2.5 mg/mL 25 ⁇ L per eye Sucrose solution (270 mOsm, pH 7-8) 1,2,4,8,12,24,48,and 96 h post administration 2 IVT PP-001 0.125 mg/eye 5 mg/mL 25 ⁇ L per eye Sucrose solution (270 mOsm, pH 7-8) 1,2,4,8,12,24,48,and 96 h post administration
  • the study director performed the IVT injection in both eyes (OU).
  • Topical ocular anesthetics were used per ASI SOPs.
  • the eyes and surrounding tissues were cleaned and disinfected with 2% betadine ophthalmic solution and then rinsed with basic salt solution (BSS).
  • BSS basic salt solution
  • injections were made 5 to 7 mm from the limbus (where the cornea meets the sclera).
  • the PP-001 or vehicle control was injected at a volume of 25 ⁇ L per eye. The needle was then removed and the eye rinsed with BSS.
  • the PP-001 was successfully administered via intravitreal injection in both eyes of 36 male Dutch Belted rabbits. No general health observations were noted for the duration of the study.
  • Vitreous humor and choroid/sclera/retina were collected from both eyes of each animal at the designated time point and analyzed for PP-001 concentration using a specific HPLC/MS/MS analytical method.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP15720340.7A 2014-05-08 2015-05-08 Compounds for treating ophthalmic diseases and disorders Active EP3139914B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14167490 2014-05-08
EP14170616 2014-05-30
PCT/EP2015/060166 WO2015169944A1 (en) 2014-05-08 2015-05-08 Compounds for treating ophthalmic diseases and disorders

Publications (3)

Publication Number Publication Date
EP3139914A1 EP3139914A1 (en) 2017-03-15
EP3139914C0 EP3139914C0 (en) 2023-07-26
EP3139914B1 true EP3139914B1 (en) 2023-07-26

Family

ID=53051826

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15720340.7A Active EP3139914B1 (en) 2014-05-08 2015-05-08 Compounds for treating ophthalmic diseases and disorders

Country Status (18)

Country Link
US (2) US11730716B2 (es)
EP (1) EP3139914B1 (es)
JP (1) JP6629840B2 (es)
KR (1) KR102312186B1 (es)
CN (2) CN116077665A (es)
AU (1) AU2015257651B2 (es)
BR (1) BR112016025997A8 (es)
CA (1) CA2947067C (es)
CL (1) CL2016002812A1 (es)
ES (1) ES2960598T3 (es)
HK (1) HK1231417A1 (es)
IL (1) IL248732B (es)
MX (1) MX2016014634A (es)
NZ (1) NZ725574A (es)
PL (1) PL3139914T3 (es)
SG (1) SG11201608835VA (es)
WO (1) WO2015169944A1 (es)
ZA (1) ZA201607260B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
ES2668934T3 (es) 2014-12-23 2018-05-23 4D Pharma Research Limited Polipéptido pirin y modulación inmune
JP6271093B1 (ja) 2014-12-23 2018-01-31 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 免疫調節
PE20180267A1 (es) 2015-06-15 2018-02-06 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
NZ777234A (en) 2015-06-15 2022-02-25 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PE20180243A1 (es) 2015-06-15 2018-01-31 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
ES2662617T3 (es) 2015-11-20 2018-04-09 4D Pharma Research Limited Composiciones que comprenden cepas bacterianas
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) * 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
JP6961879B2 (ja) * 2015-12-30 2021-11-05 レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
CN114712405A (zh) 2016-03-04 2022-07-08 4D制药有限公司 包含细菌菌株的组合物
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
RS61872B1 (sr) 2017-05-22 2021-06-30 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
JP6978514B2 (ja) 2017-05-24 2021-12-08 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
AU2018285445B2 (en) 2017-06-14 2020-03-26 Cj Bioscience, Inc. Compositions comprising bacterial strains
HUE052319T2 (hu) 2017-06-14 2021-04-28 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
EP3600364B1 (en) 2017-06-14 2020-08-05 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus megasphaera and uses thereof
CN110944668A (zh) 2017-06-16 2020-03-31 学校法人同志社 用于治疗或预防眼部症状、障碍或疾病的包含mTOR抑制剂的药物及其应用
JPWO2018230713A1 (ja) * 2017-06-16 2020-04-16 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
TWI818954B (zh) 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
CN111163757B (zh) * 2018-03-09 2022-04-19 帕诺泰斯制药有限公司 眼用制剂
US12037305B2 (en) * 2018-03-16 2024-07-16 Immunic Ag Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents
US10889548B2 (en) 2018-03-26 2021-01-12 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
US20210290651A1 (en) 2020-03-20 2021-09-23 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
CN116322773A (zh) * 2020-04-21 2023-06-23 马萨诸塞大学 用于治疗年龄相关性黄斑变性的方法和组合物
CN111638341A (zh) * 2020-07-01 2020-09-08 山东凯歌智能机器有限公司 一种检测小细胞肺癌患者外周血循环肿瘤细胞pd-l1基因突变的试剂盒及检测方法
JP2023545788A (ja) * 2020-10-15 2023-10-31 アスラン ファーマスーティカルズ ピーティーイー エルティーディー ジヒドロオロト酸デヒドロゲナーゼ（ｄｈｏｄｈ）阻害剤による自己免疫疾患の治療
EP4320100A1 (en) 2021-04-09 2024-02-14 Immunic AG Deuterated dhodh inhibitors
TW202332433A (zh) 2021-12-23 2023-08-16 德商埃慕尼克股份公司 含羧酸生物電子等排體之dhodh抑制劑
US20230278979A1 (en) * 2022-03-01 2023-09-07 Kiora Pharmaceuticals Gmbh Salts of a dihydroorotate dehydrogenase (dhod) inhibitor
AU2023230874A1 (en) * 2022-03-09 2024-09-19 Kiora Pharmaceuticals Gmbh Polymorphs of a dihydroorotate dehydrogenase (dhod) inhibitor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD297328A5 (de) * 1989-08-18 1992-01-09 �������@���������k���Kk�� 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
AU2003301347A1 (en) * 2002-10-17 2004-05-04 Control Delivery Systems, Inc. Methods for monitoring treatment of disease
WO2004056746A1 (en) * 2002-12-23 2004-07-08 4Sc Ag Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
EP1581478A1 (en) * 2002-12-23 2005-10-05 4Sc Ag Dhodh-inhibitors and method for their identification
CN1732147A (zh) * 2002-12-23 2006-02-08 4Sc股份公司 作为抗炎、免疫调节和抗增殖试剂的环烯二羧酸化合物
JP2006089485A (ja) * 2004-08-24 2006-04-06 Santen Pharmaceut Co Ltd ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
WO2006022442A1 (ja) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
WO2007038687A2 (en) * 2005-09-27 2007-04-05 Aciont, Inc. Ocular administration of immunosuppressive agents
ES2319596B1 (es) * 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
TWI530286B (zh) 2009-05-04 2016-04-21 帕納特斯製藥格斯有限公司 作為抑制病毒化合物之抗發炎劑
US20110021465A1 (en) * 2009-07-23 2011-01-27 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
CA2838289C (en) * 2011-06-10 2019-09-10 Ramscor, Inc. Sustained release formulations for delivery of proteins to the eye and methods of preparing same
AU2014390300A1 (en) * 2014-04-11 2016-10-20 Panoptes Pharma Gmbh Anti-inflammatory agents as virostatic compounds

Also Published As

Publication number Publication date
SG11201608835VA (en) 2016-11-29
KR20160147023A (ko) 2016-12-21
EP3139914C0 (en) 2023-07-26
US20230285355A1 (en) 2023-09-14
JP2017514917A (ja) 2017-06-08
US11730716B2 (en) 2023-08-22
BR112016025997A2 (pt) 2017-08-15
ES2960598T3 (es) 2024-03-05
CN116077665A (zh) 2023-05-09
KR102312186B1 (ko) 2021-10-14
AU2015257651A1 (en) 2016-11-10
CN106572968A (zh) 2017-04-19
EP3139914A1 (en) 2017-03-15
CA2947067A1 (en) 2015-11-12
ZA201607260B (en) 2018-05-30
US20170071904A1 (en) 2017-03-16
HK1231417A1 (zh) 2017-12-22
WO2015169944A1 (en) 2015-11-12
JP6629840B2 (ja) 2020-01-15
IL248732B (en) 2019-07-31
CA2947067C (en) 2023-02-14
AU2015257651B2 (en) 2020-01-23
MX2016014634A (es) 2017-04-10
NZ725574A (en) 2022-08-26
PL3139914T3 (pl) 2023-11-27
BR112016025997A8 (pt) 2021-07-06
IL248732A0 (en) 2017-01-31
CL2016002812A1 (es) 2017-03-17

Similar Documents

Publication Publication Date Title
US20230285355A1 (en) Compounds for treating ophthalmic diseases and disorders
Schopf et al. Topical ocular drug delivery to the back of the eye by mucus-penetrating particles
AU2011284589B2 (en) Compounds for the treatment/prevention of ocular inflammatory diseases
AU2017301410B2 (en) Multikinase inhibitors and uses in ocular fibrosis
Reijerkerk et al. Systemic treatment with glutathione PEGylated liposomal methylprednisolone (2B3-201) improves therapeutic efficacy in a model of ocular inflammation
Fang et al. Immune modulating nanoparticles for the treatment of ocular diseases
WO2020009248A1 (ja) 眼組織の線維化抑制用組成物
CA3088185C (en) Suspension compositions of multi-target inhibitors
US20230025836A1 (en) Eye drop composition for preventing or treating eye disease
US8877183B2 (en) Methods for treatment of ocular diseases
US20240226180A1 (en) Methods and compositions for treating dry eye, tear hyperosmolarity, and other ocular conditions
Koike et al. Trabeculotomy in a Behcet’s disease patient one week after infliximab administration
JP2024534570A (ja) 眼炎症性疾患を処置する方法
TW202227042A (zh) 雙重鎮痛／消炎組合物、組合及其使用方法
CN114028421A (zh) 一种使用泊洛沙姆用于治疗眼部疾病的方法
JP2002356431A (ja) ステロイドを有効成分とする網脈絡膜疾患治療剤
FR2963238A1 (fr) Derives de 15-desoxyspergualine pour le traitement et/ou la prevention des maladies inflammatoires oculaires
WO2014115011A1 (en) Compositions for use in treating eye disorders using opioid receptor antagonists

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180910

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220809

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PANOPTES PHARMA GES.M.B.H.

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230220

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: KIORA PHARMACEUTICALS GMBH

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015084754

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20230825

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI

Effective date: 20230901

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231027

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230726

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231026

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231126

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230726

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231027

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2960598

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20240305

RAP4 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: KIORA PHARMACEUTICALS GMBH

U1H Name or address of the proprietor changed [after the registration of the unitary effect]

Owner name: KIORA PHARMACEUTICALS GMBH; AT

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015084754

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230726

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230726

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230726

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230726

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20240429

U20 Renewal fee paid [unitary effect]

Year of fee payment: 10

Effective date: 20240527

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240521

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240602

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240627

Year of fee payment: 10